KATHMANDU, APRIL 21 The Department of Drug Administration has ordered the immediate recall of a batch of Ondatron-4 (Ondansetron 4mg) tablets from the market after laboratory testing found the product to be substandard. Issuing a notice on Monday, the department said samples collected during routine market surveillance were tested at the National Medicine Laboratory, which found that batch number ONDT2901 - manufactured in August 2025 and due to expire in July 2027 - did not comply with the IP 2022 standard with respect to the assay test. The batch was manufactured by Deurali-Janata Pharmaceuticals Pvt. Ltd. of Dapasi, Kathmandu. Under Section 14 of the Drug Act 2035, the department has suspended the sale and distribution of the affected batch and directed the manufacturer and its representatives to withdraw all units from the market immediately and submit a report to the department. All concerned parties - including prescribers, distributors and retailers - have been requested not to prescribe, sell, distribute or use medicines bearing the said batch number. Ondansetron is widely used as an anti-nausea and anti-vomiting medication, commonly prescribed following surgery or chemotherapy.